Generic tofacitinib (Xeljanz®) has officially entered the market – an important shift in the JAK inhibitor category. With launches across multiple manufacturers…
As biosimilars continue to reshape the market, plan sponsors are looking for real savings – without added complexity. ProAct’s new BioPathways™ Program delivers targeted, clinically-aligned utilization management…
On April 23, 2026, the FDA granted accelerated approval to Otarmeni™ (lunsotogene parvec‑cwha) from Regeneron Pharmaceuticals – the first FDA‑approved gene therapy for patients with…
Gene therapy is an emerging class of treatment that targets disease at its source by repairing or replacing a faulty gene. Unlike traditional drugs that require ongoing use, many gene therapies…
Foundayo™ (orforglipron), Eli Lilly’s once‑daily oral GLP‑1 receptor agonist, was FDA‑approved on April 1, 2026 for chronic weight management in adults with obesity or overweight plus at least one weight‑related comorbidity…
